Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Disruptive Pharma

1.40 SEK-5.91 %24.8. klo 18.25
Less than 1K followers

DPHA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-5.91 %
+0.14 %
+4.78 %
-16.30 %
-4.63 %
-93.71 %
-83.57 %
-97.88 %
-99.92 %

Guard Therapeutics is engaged in the development of drugs in the field of oxidative stress. The company focuses primarily on research, development and commercialization of drugs that aim to prevent the onset and complications of acute kidney injury. The drug has been shown in preclinical studies to protect exposed tissue and support regenerative processes. The company is headquartered in Lund.

Read more
Market cap
62.51M SEK
Turnover
86.67K SEK
Revenue
EBIT %
P/E
Dividend yield-%
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Financial calendar
12.11.
2026

Interim report Q3'26

18.2.
2027

Annual report '26

Press release18.08.2026 klo 18.20

Disruptive Pharma to ring the opening bell at Nasdaq Stockholm

Disruptive Pharma
Regulatory press release27.07.2026 klo 17.30

Guard Therapeutics Completes Reverse Takeover of Disruptive Pharma and Executes In-Kind Share Issue

Disruptive Pharma
Regulatory press release16.07.2026 klo 22.00

Guard Therapeutics Receives Conditional Approval for Continued Listing on Nasdaq First North Growth Market and Publishes Company Description

Disruptive Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release12.06.2026 klo 09.40

Guard Therapeutics Initiates Transaction Process for the GTX Platform

Disruptive Pharma
Regulatory press release10.06.2026 klo 20.50

Guard Therapeutics has entered into a conditional agreement for a reverse takeover with Disruptive Pharma

Disruptive Pharma
Regulatory press release09.04.2026 klo 18.10

Guard Therapeutics provides information regarding observation status on Nasdaq First North Growth Market

Disruptive Pharma
Press release31.03.2026 klo 16.45

Guard Therapeutics provides update on strategic review

Disruptive Pharma
Regulatory press release05.02.2026 klo 17.45

Guard Therapeutics Announces Changes to the Company’s Management Team

Disruptive Pharma
Press release05.02.2026 klo 17.35

Guard Therapeutics Provides Status Update Regarding Ongoing Strategic Review

Disruptive Pharma
Press release15.01.2026 klo 17.55

Guard Therapeutics Partners in EU Consortium For Alport Syndrome

Disruptive Pharma
Press release30.12.2025 klo 15.20

DNB Carnegie Access: Guard Therapeutics: Discontinuing coverage

Disruptive Pharma
Regulatory press release16.12.2025 klo 15.20

Guard Therapeutics presents the Nomination Committee for 2026

Disruptive Pharma
Press release08.12.2025 klo 17.00

Guard Therapeutics appoints Redeye as financial advisor in the strategic review

Disruptive Pharma
Regulatory press release05.12.2025 klo 15.40

Guard Therapeutics changes Certified Adviser to Redeye AB

Disruptive Pharma
Press release05.12.2025 klo 07.21

DNB Carnegie Access: Guard Therapeutics: Challenging path forward

Disruptive Pharma
Regulatory press release04.12.2025 klo 20.50

Guard Therapeutics Explores Strategic Alternatives

Disruptive Pharma
Press release04.12.2025 klo 20.45

Guard Therapeutics Provides Assessment of Full POINTER Study Results

Disruptive Pharma
Press release13.11.2025 klo 18.17

DNB Carnegie Access: Guard Therapeutics: Awaiting further company communication – Q3 review

Disruptive Pharma
Press release27.10.2025 klo 10.33

DNB Carnegie Access: Guard Therapeutics: POINTER data – endpoints not met

Disruptive Pharma
Regulatory press release26.10.2025 klo 12.45

Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study

Disruptive Pharma